Medifast Analyst Ratings
Medifast Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/13/2023 | 19.05% | Stephens & Co. | → $82 | Initiates Coverage On | → Equal-Weight |
| 08/08/2023 | 16.14% | DA Davidson | $93 → $80 | Maintains | Neutral |
| 07/31/2023 | 35.02% | DA Davidson | $75 → $93 | Maintains | Neutral |
| 05/02/2023 | 3.08% | DA Davidson | $94 → $71 | Maintains | Neutral |
| 02/22/2023 | 36.47% | DA Davidson | $106 → $94 | Maintains | Neutral |
| 11/04/2022 | 53.89% | DA Davidson | $278 → $106 | Downgrades | Buy → Neutral |
| 08/04/2022 | 303.6% | DA Davidson | $352 → $278 | Maintains | Buy |
| 08/04/2022 | 117.77% | Jefferies | $345 → $150 | Downgrades | Buy → Hold |
| 06/02/2022 | 411.03% | DA Davidson | $341 → $352 | Maintains | Buy |
| 02/24/2022 | 395.06% | DA Davidson | $349 → $341 | Maintains | Buy |
| 11/08/2021 | 406.68% | DA Davidson | $395 → $349 | Maintains | Buy |
| 05/05/2021 | 473.46% | DA Davidson | $302 → $395 | Maintains | Buy |
| 02/26/2021 | 338.44% | DA Davidson | $239 → $302 | Maintains | Buy |
| 01/25/2021 | 284.73% | Jefferies | $205 → $265 | Upgrades | Hold → Buy |
| 01/12/2021 | 246.98% | DA Davidson | $205 → $239 | Maintains | Buy |
| 11/05/2020 | 197.62% | DA Davidson | $180 → $205 | Upgrades | Neutral → Buy |
| 06/25/2020 | 138.1% | B. Riley Securities | → $164 | Initiates Coverage On | → Buy |
| 05/06/2020 | 24.85% | DA Davidson | $83 → $86 | Maintains | Neutral |
| 02/27/2020 | 20.5% | DA Davidson | $74 → $83 | Maintains | Neutral |
| 11/08/2019 | 7.43% | DA Davidson | $250 → $74 | Downgrades | Buy → Neutral |
| 07/25/2019 | 88.73% | Jefferies | → $130 | Initiates Coverage On | → Buy |
| 02/27/2019 | 213.59% | Sidoti & Co. | $211 → $216 | Maintains | Buy |
| 11/08/2018 | — | Sidoti & Co. | Upgrades | Neutral → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月13日 | 19.05% | 斯蒂芬斯公司 | →$82 | 开始承保 | →等重 |
| 2023/08/08 | 16.14% | 达·戴维森 | $93→$80 | 维护 | 中性 |
| 07/31/2023 | 35.02% | 达·戴维森 | $75→$93 | 维护 | 中性 |
| 05/02/2023 | 3.08% | 达·戴维森 | $94→$71 | 维护 | 中性 |
| 02/22/2023 | 36.47% | 达·戴维森 | $106→$94 | 维护 | 中性 |
| 11/04/2022 | 53.89% | 达·戴维森 | $278→$106 | 评级下调 | 购买→中性 |
| 08/04/2022 | 303.6% | 达·戴维森 | $352→$278 | 维护 | 买 |
| 08/04/2022 | 117.77% | 杰富瑞 | $345→$150 | 评级下调 | 购买→Hold |
| 06/02/2022 | 411.03% | 达·戴维森 | $341→$352 | 维护 | 买 |
| 02/24/2022 | 395.06% | 达·戴维森 | $349→$341 | 维护 | 买 |
| 11/08/2021 | 406.68% | 达·戴维森 | $395→$349 | 维护 | 买 |
| 05/05/2021 | 473.46% | 达·戴维森 | $302→$395 | 维护 | 买 |
| 02/26/2021 | 338.44% | 达·戴维森 | $239→$302 | 维护 | 买 |
| 2021/01/25 | 284.73% | 杰富瑞 | $205→$265 | 升级 | 持有→购买 |
| 2021/12/01 | 246.98% | 达·戴维森 | $205→$239 | 维护 | 买 |
| 11/05/2020 | 197.62% | 达·戴维森 | $180→$205 | 升级 | 中性→购买 |
| 06/25/2020 | 138.1% | B.莱利证券 | →$164 | 开始承保 | →购买 |
| 05/06/2020 | 24.85% | 达·戴维森 | $83→$86 | 维护 | 中性 |
| 02/27/2020 | 20.5% | 达·戴维森 | $74→$83 | 维护 | 中性 |
| 2019年8月11日 | 7.43% | 达·戴维森 | $250→$74 | 评级下调 | 购买→中性 |
| 2019年07月25日 | 88.73% | 杰富瑞 | →$130 | 开始承保 | →购买 |
| 2019年02月27日 | 213.59% | 西多蒂公司 | $211→$216 | 维护 | 买 |
| 2018/08/11 | - | 西多蒂公司 | 升级 | 中性→购买 |
What is the target price for Medifast (MED)?
Medifast(MED)的目标价格是多少？
The latest price target for Medifast (NYSE: MED) was reported by Stephens & Co. on October 13, 2023. The analyst firm set a price target for $82.00 expecting MED to rise to within 12 months (a possible 19.05% upside). 6 analyst firms have reported ratings in the last year.
史蒂芬斯公司于2023年10月13日公布了Medifast(纽约证券交易所市场代码：MED)的最新目标价。这家分析公司将目标价定为82.00美元，预计MED将在12个月内上涨(可能上涨19.05%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Medifast (MED)?
Medifast(MED)的最新分析师评级是多少？
The latest analyst rating for Medifast (NYSE: MED) was provided by Stephens & Co., and Medifast initiated their equal-weight rating.
对Medifast(纽约证券交易所市场代码：MED)的最新分析师评级是由Stephens&Co.提供的，Medifast启动了他们的同等权重评级。
When is the next analyst rating going to be posted or updated for Medifast (MED)?
Medifast(MED)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Medifast的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Medifast的上一次评级是在2023年10月13日提交的，因此您应该预计下一次评级将在2024年10月13日左右提供。
Is the Analyst Rating Medifast (MED) correct?
分析师对Medifast(MED)的评级正确吗？
While ratings are subjective and will change, the latest Medifast (MED) rating was a initiated with a price target of $0.00 to $82.00. The current price Medifast (MED) is trading at is $68.88, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Medifast(MED)评级是以0.00美元至82.00美元的目标价启动的。Medifast(MED)目前的交易价格为68.88美元，在分析师的预测范围内。